Skip to content
Peptide Atlas
All peptides

Matrixyl

Tier 2 · Preclinical
Also known as Palmitoyl pentapeptide-4 · Pal-KTTKS · Matrixyl 3000

The strongest evidence is Tier 1 human randomized controlled trials, including the Robinson et al. (2005) 12-week double-blind placebo-controlled split-face study (n=93), Lintner et al. (n=94, PMID 17696523), Aruan et al. (2023, n=21), Kaur et al. (n=48), Scherdin et al. (n=125), and several Sederma (manufacturer) pivotal trials, plus a 2018 systematic review citing 10+ RCTs in 1,000+ subjects. However, much of the mechanistic and dermal-delivery evidence is Tier 2 (in vitro human fibroblast cultures and rodent models). Clinical trials are generally small, frequently manufacturer-linked, and predominantly conducted in Caucasian women (only Aruan 2023 studied Asian skin). Reported effect sizes and penetration figures vary widely, and several notable claims rest on single, lower-tier sources.

Half-life
Not recorded
Routes
Topical
Goals
Anti-aging / skin rejuvenation · Wrinkle and fine line reduction · Skin firmness and elasticity · Wound healing (preclinical)
Cost / mg
Not recorded

How it works

Matrixyl is the trade name for palmitoyl pentapeptide-4 (Pal-KTTKS), a lab-made peptide made by attaching a fatty acid (palmitic acid) to a five-amino-acid chain (KTTKS) originally found as a fragment of type I collagen. It acts as a 'matrikine' — a messenger peptide that signals skin cells called fibroblasts to behave as if collagen has been damaged and needs rebuilding. In response, fibroblasts increase production of collagen, fibronectin, and other components of the skin's supportive matrix. The attached fatty acid makes the otherwise water-loving peptide able to slip through the skin's oily outer barrier to reach the dermis. In human trials this translates into modest, measurable reductions in wrinkles and improvements in skin texture and firmness, with very good tolerability.

Overview

Overview

Matrixyl is the trade name for palmitoyl pentapeptide-4 (Pal-KTTKS), a synthetic lipopeptide consisting of the pentapeptide lysine-threonine-threonine-lysine-serine (KTTKS) conjugated to palmitic acid, a 16-carbon saturated fatty acid. It is also known as palmitoyl pentapeptide-3, Pal-KTTKS, and Micro-Collagen. (Matrixyl 3000 is a separate, related product — a combination of palmitoyl tripeptide-1 and palmitoyl tetrapeptide-7 — not another name for palmitoyl pentapeptide-4.) Most sources give a molecular formula of C39H75N7O10 and molecular weight of approximately 802 g/mol (CAS 214047-00-4, PubChem CID 9897237), although one source reports ~678 Da for the core peptide and ~1,000 Da with the lipid modification.

Matrixyl was developed by Sederma SAS (now part of Croda International) and launched in 2000 as the first peptide active ingredient specifically designed for anti-aging cosmetic applications. It appears in over 1,500 commercial skincare products worldwide.

Origin and Rationale

The KTTKS sequence was originally identified in 1993 by Katayama et al. at the University of Tennessee as a subfragment of the C-terminal propeptide of type I procollagen. It was determined to be the minimum sequence capable of retaining approximately 80% of the parent fragment's activity in stimulating extracellular matrix production by human dermal fibroblasts. In the original screening work, subfragments R9 and R11 stimulated collagen and fibronectin production 6–8 fold in human lung fibroblasts before KTTKS was pinned down as the minimum active sequence.

Matrixyl belongs to the class of signal peptides known as matrikines — messenger peptides derived from extracellular matrix proteins that regulate cell activity through specific receptor interactions. By mimicking a fragment of degraded collagen, it signals fibroblasts to increase collagen synthesis. The palmitoyl modification was introduced by Lintner and colleagues at Sederma to overcome the poor skin permeation of the unmodified hydrophilic pentapeptide; the reported magnitude of penetration enhancement is contested, ranging from 5–10 fold to 100–1000 fold across sources.

Mechanism

In vitro, Matrixyl stimulates dermal fibroblast production of collagen types I, III, and IV, fibronectin, and glycosaminoglycans in a dose- and time-dependent manner, with effects evident within about 4 hours. Proposed mechanisms include activation of fibroblast surface receptors triggering MAPK/ERK signaling, mild inhibition of matrix metalloproteinases (MMPs), and (per one source) interaction with TGF-beta receptors with stimulation of hyaluronic acid synthesis. However, the precise receptor target remains unidentified, and several downstream mechanisms (epidermal thickening, GAG inhibition, TGF-beta interaction) are expert-opinion or theoretical rather than demonstrated in humans. C16-KTTKS also self-assembles into nanotape structures, and this self-assembly is linked to its collagen-stimulating activity.

Clinical Evidence

The pivotal human trial is Robinson et al. (2005), a 12-week double-blind, placebo-controlled, split-face study of 93 women aged 35–55, in which a moisturizer containing just 3 ppm (0.0003%) Pal-KTTKS applied twice daily produced significant improvements in wrinkle and fine-line reduction versus moisturizer alone, confirmed by quantitative image analysis and expert graders. A companion head-to-head evaluation reported that Matrixyl matched retinol's wrinkle reduction (~20% vs 17%) with zero irritation, while 40% of the retinol group experienced erythema.

Additional trials — including Lintner et al. (n=94, PMID 17696523), Kaur et al. (n=48), Scherdin et al. (n=125, dose-dependent periorbital improvement), Aruan et al. (2023, n=21, the only trial in Asian skin), and several Sederma studies — reported reductions in wrinkle depth, fold thickness, and skin rigidity, along with histological changes including increased elastin density and dermal-epidermal junction remodeling. A 2018 systematic review found moderate efficacy (10–30% wrinkle reduction versus baseline). Cited effect sizes vary widely (from ~10–30% up to 45% for deep wrinkles with Matrixyl 3000 and 68% at 4 ppm in a single lower-tier source), with higher figures often from vendor-linked sources.

Related Variants

  • Matrixyl 3000 combines palmitoyl tripeptide-1 (pal-GHK, collagen stimulation) and palmitoyl tetrapeptide-7 (pal-GQPR, reduces inflammation via lower IL-6).
  • Matrixyl Synthe-6 (palmitoyl tripeptide-38) is reported to stimulate collagens I, III, and IV, fibronectin, hyaluronic acid, and laminin-5.

Preclinical / Other Findings

Animal and in vitro work has explored Matrixyl in wound healing (accelerated closure, increased collagen deposition, improved angiogenesis in rodent models), tendon cells (increased type I collagen and TGF-beta), reduction of myofibroblast trans-differentiation, and synergy with i-PRF. Novel KTTKS conjugates (ionic-liquid IL-KTTKS) showed antibacterial, antifungal and collagenesis-inducing action, and palmitoyl KTTKS peptides act as potent plasmin inhibitors. Effects are considered more modest than prescription retinoids and are cosmetic in nature, delivering measurable but not deep remodeling improvements.

What the research shows

253 findings extracted from the 31 sources cited below, strongest evidence first within each group. Every one links to the source it came from.

What human studies found

Based on 28 human trial findings, 10 human study findings, 8 animal findings, 8 in vitro findings and 5 expert opinion findings.

  • human trialRobinson et al. (2005) — 12-week RCT with 93 women applying palmitoyl pentapeptide-4 cream or placebo twice daily for 12 weeks showed statistically significant reductions in fine lines and wrinkles versus placebo1

  • human trialLintner (2005) — 28-day double-blind trial with 0.005% palmitoyl pentapeptide-4 cream applied twice daily to periorbital area produced 18% decrease in fold depth, 37% reduction in fold thickness, and 21% improvement in skin firmness1

  • human trialAruan et al. (2023) — Double-blind randomized trial with 21 Indonesian women compared palmitoyl pentapeptide-4 cream against Argireline cream and placebo over eight weeks; palmitoyl pentapeptide-4 outperformed both1

  • human trialSederma's 2-month blinded randomized split-face trial on 28 subjects with Matrixyl 3000 showed deep wrinkles area shrank by 45% and skin tonicity increased by nearly 20%1

  • human trialPalmitoyl tripeptide-1 alone in 15 women for four weeks of twice-daily application produced significant reductions in wrinkle length, depth, and roughness1

  • human trialApplied in a split-face design for 8 weeks, the serum produced statistically significant wrinkle reductions for crow's feet2

  • human trialApplied in a split-face design for 8 weeks, the serum produced statistically significant improvements in skin elasticity2

  • human trialApplied in a split-face design for 8 weeks, the serum produced statistically significant improvements in barrier function2

Show the remaining 51

  • human trial2005 trial with Pal-KTTKS (93 subjects, 12 weeks, double-blind placebo-controlled split-face design) showed significant wrinkle and fine line improvement2

  • human trialSederma histological study (~2006) with Pal-KTTKS (49 subjects, 4 months, double-blind placebo-controlled) showed improved roughness, wrinkle depth, and increased elastin density2

  • human trial7% PPP-4 serum study with Pal-KTTKS (7%, 15 subjects, 8 weeks, split-face design) showed significant wrinkle reduction2

  • human trialMultiple independent studies confirm modest but real improvements in fine lines, wrinkle depth, and skin texture at very low concentrations2

  • human trialClinical studies show significant wrinkle and fine line reduction vs placebo after 12 weeks of topical application3

  • human trialIn a 12-week, double-blind, placebo-controlled, split-face study of 93 women (aged 35-55), topical application of a moisturizer containing 3 ppm Pal-KTTKS provided significant improvement in wrinkle and fine line reduction compared to the moisturizer alone3

  • human trialPal-KTTKS at 3 ppm provided significant improvement vs. placebo control for reduction in wrinkles/fine lines by quantitative technical analysis5

  • human trialPal-KTTKS at 3 ppm provided significant improvement vs. placebo control for reduction in wrinkles/fine lines by expert grader image analysis5

  • human trialSubjects reported significant fine line/wrinkle improvements in self-assessments5

  • human trialSubjects noted directional effects for other facial improvement parameters in self-assessments5

  • human trialTopical Pal-KTTKS provided significant improvement in wrinkles and fine lines vs placebo by quantitative image analysis in a 12-week, double-blind, placebo-controlled, split-face study of 93 women aged 35-557

  • human trialExpert graders confirmed wrinkle reduction on the Pal-KTTKS-treated side7

  • human trialRobinson and colleagues published a 12-week, double-blind, placebo-controlled, split-face, randomized study in 93 Caucasian women25

  • human trial10-30% wrinkle depth reduction demonstrated in multiple RCTs over 8-12 weeks28

  • human trial10+ RCTs involving 1,000+ subjects28

  • human trial2018 systematic review found moderate efficacy (10-30% wrinkle reduction vs baseline) across published trials28

  • human trialLintner et al. (n=94, PMID: 17696523): RCT demonstrated significant improvement in photoaged skin after 8 weeks of twice-daily application vs vehicle control28

  • human trialSederma pivotal study (n=60): 30% wrinkle depth reduction after 12 weeks of use28

  • human trialKaur et al. (n=48): Matrixyl 3000 showed superiority over control cream for facial wrinkle reduction28

  • human trialScherdin et al. (n=125): Dose-dependent improvement in periorbital wrinkles28

  • human studySederma female study (~2007) with Matrixyl 3000 showed -45% deep wrinkle area and +20% tonicity over 2 months2

  • human studyAdditional studies have reported reductions in wrinkle depth (18%), fold thickness (37%), and skin rigidity (21%) after 28 days of twice-daily application3

  • human studyThe two lipopeptides stimulate collagen production in Human Dermal Fibroblasts (HDFa) at low concentration4

  • human studyRobinson et al. compared palmitoyl pentapeptide-4 to retinol and found that Matrixyl produced comparable wrinkle reduction to retinol22

  • human studyMatrixyl increased type I collagen synthesis by up to 117%22

  • human studyAt 4 ppm concentration, Matrixyl can reduce wrinkle depth by up to 68% after two months of twice-daily application22

  • human studyIn a study of 50 people, Matrixyl reduced wrinkle depth by 20 percent over 12 weeks — about the same as retinol, but without the redness and peeling that retinol causes26

  • human studyRobinson et al. (2005) ran a trial of 50 subjects over 12 weeks, head-to-head against retinol with a vehicle control26

  • human studyMatrixyl matched retinol's wrinkle reduction (20% vs. 17%) with zero irritation — while 40% of the retinol group experienced erythema26

  • human study3 ppm (0.0003%) Pal-KTTKS in moisturizer applied twice daily for 12 weeks showed significant improvement in wrinkles and fine lines vs placebo moisturizer in 93 women aged 35-5529

  • animalIn cellular and animal photoaging experiments, GAO/PAL-4-SM possessed remarkable capabilities in boosting collagen and hyaluronic acid regeneration, mitigating inflammation and apoptosis, accelerating macrophage M2 polarization, thereby lessening skin wrinkles and leveraging elasticity8

  • animalKTTKS-CBC composites exhibited significantly better wound healing capability with alleviated inflammation, increased collagen deposition, improved angiogenesis, and accelerated wound closure in rat burn wound model11

  • animalMSC-KTTKS-CBC composites showed the best wound-healing performance among all treatment groups in rat model11

  • animalMatrixyl (MTI) can lead to a faster healing process14

  • animalWound healing was improved from 63.5 up to 81.81% in treatment groups compared to negative control group14

  • animalC-MTI-1 and P-MTI-1 had a larger impact on wound healing compared to positive control group (Comfeel)14

  • animalRejuvenation of skin appendage was visible in both groups of cream and patches with MTI14

  • animalRe-epithelialization had a higher range for patch with MTI in comparison with cream containing MTI and positive control14

  • in vitroEnhanced extracellular matrix synthesis, improved dermal density, collagen remodeling demonstrated in vitro6

  • in vitroIn vitro evidence shows fibroblast viability and ECM gene upregulation6

  • in vitroMatrixyl alone led to effects on human dermal fibroblast viability and proliferation9

  • in vitroWhen delivered with PC liposomes, pal-KTTKS stimulated collagen production more than free pentapeptide10

  • in vitroPC liposome-delivered pal-KTTKS stimulated collagen production more than 1 mM ascorbic acid positive control10

  • in vitroα-SMA-positive stress fibers per field decreased twofold with 0.1 µM Pal-KTTKS treatment (75 ± 7.1 vs 38.6 ± 16.1%)17

  • in vitroMatrixyl shows dose-dependent effects on fibroblast collagen production in vitro22

  • in vitroStimulates collagen I production by 100-200% in skin explants28

  • expert opinionGHK-Cu (copper peptide) has a broader evidence base spanning 50+ years of research, with wrinkle-reduction data comparable to Matrixyl's2

  • expert opinionSigal peptides have garnered remarkable efficacy in rejuvenating photoaged skin and delaying senescence8

  • expert opinionMatrixyl has a relatively strong clinical evidence base21

  • expert opinionAfamelanotide (Scenesse) is the FDA-approved pharmaceutical formulation with proven safety and efficacy from Phase 3 clinical trials, delivered as a controlled-release subcutaneous implant24

  • expert opinionEffects are more modest than prescription retinoids29

How it works

Based on 1 human trial finding, 1 human study finding, 6 animal findings, 41 in vitro findings, 28 expert opinion findings and 9 theoretical findings.

  • human trialStimulates collagen types I and III synthesis by fibroblasts through matrikine signaling3

  • human studySederma four-month histological study showed structural changes at the dermal-epidermal junction (collagen IV, elastin fibers)2

  • animalpal-KTTKS incorporated into carboxylated cellulose stimulates collagen synthesis11

  • animalDDKT enhanced collagen deposition and by day 20 DDKT-treated groups had developed dense collagen network accompanied by regenerated epidermis12

  • animalNumber of blood vessels in DDKT-treated diabetic wounds was significantly higher than in control groups with substantially enhanced neovascularization12

  • animalDDKT exhibits remarkable pro-vascularization capability12

  • animalThe contribution of MTI to collagen formation during wound healing depends on its mode of delivery and its release over time14

  • animalA Journal of Orthopaedic Research study found KTTKS promoted type I collagen and transforming growth factor-beta expression in tendon cells25

Show the remaining 78

  • in vitroLipopeptide C-KTTKS self-assembles into nanotapes based on a multi-bilayer stacking across a pH range pH 4-7 and micelles at pH 24

  • in vitroC-RTTRS forms a substantial population of spherical micelles for the acetate salt for pH 2-7, but mainly nanotapes for the TFA salt for pH 4-74

  • in vitroNo significant effect of the counterion was noted on cell viability or collagen production4

  • in vitroMatrixyl is a synthetic pentapeptide (KTTKS) derived from pro-collagen I fragment, N-palmitoylated for lipophilicity6

  • in vitroPrimary target is Dermal fibroblasts6

  • in vitroMechanism: Fibroblast stimulation → Collagen I/III/IV synthesis → Glycosaminoglycan deposition → ECM remodeling6

  • in vitroSubfragments R9 and R11 stimulated collagen and fibronectin production 6-8 fold in human lung fibroblasts7

  • in vitroR12 (residues 197-216) containing the overlap region was active in stimulating extracellular matrix production7

  • in vitroKTTKS was identified as the minimum active sequence7

  • in vitroGAO ILs facilitated PAL-4 permeation by enhancing its miscibility and interaction with stratum corneum (SC)8

  • in vitroMatrixyl (palmitoyl pentapeptide-4) is studied for its ability to stimulate collagen synthesis and remodel the extracellular matrix9

  • in vitroi-PRF combined with Matrixyl increased cell viability and upregulated ECM-related genes at 72 h9

  • in vitroThe combination of i-PRF + Matrixyl showed synergistic effects on dermal fibroblasts9

  • in vitroInclusion of amphiphilic N-palmitoyl-KTTKS peptide within phospholipid-based vesicles could improve peptide stability and skin delivery10

  • in vitroIL-KTTKS conjugates present potent activity against antibiotic-susceptible strains and multidrug resistant clinical isolates of Gram-positive and Gram-negative bacterial species13

  • in vitroIL-KTTKS antibacterial activity is preserved in simulated wound fluid13

  • in vitroIL-KTTKS collagenesis-inducing effects are comparable to or stronger than those of Matrixyl13

  • in vitroIL-KTTKS exert triple antibacterial, antifungal, and collagenesis-inducing action13

  • in vitroKTTKS minimally crosses the skin because of hydrophilicity15

  • in vitroPalmitoylation demonstrated sharp peaks in the XRD pattern of KTTKS15

  • in vitroKTTKS is a matrikine that originates from the proteolytic hydrolysis of collagen16

  • in vitroKTTKS stimulates ECM production and types I and III collagen expression in vitro16

  • in vitroPal-KTTKS (palmitoyl pentapeptide-3) is a more stable form of KTTKS16

  • in vitroPalmitoyl peptides were the most active plasmin inhibitors, whether in acid or amide form16

  • in vitroNo biological effects of lysine modification to arginine in the synthesized peptides were found16

  • in vitroThree peptide compounds showed cell growth in fibroblast tests16

  • in vitroThree compounds showed no concentration-activity relationship in the collagen and DNA biosynthesis assays16

  • in vitroPalmitoyl-pentapeptide (Pal-KTTKS) is a lipidated subfragment of type 1 pro-collagen (residues 212-216)17

  • in vitroPal-KTTKS at 0.1 µM reduces α-SMA expression and trans-differentiation of fibroblasts to myofibroblast17

  • in vitroThe inhibitory effect of Pal-KTTKS on α-SMA-positive stress fibers was not significant at 0.5 µM treatment17

  • in vitroThe degree of reduction in fibroblast to myofibroblast trans-differentiation is dose-dependent17

  • in vitroStress fiber level and collagen contractility correlates with α-SMA expression level17

  • in vitroWhen protease inhibitors were added, the stability of both compounds (KTTKS and pal-KTTKS) improved significantly18

  • in vitroC16-KTTKS (Matrixyl) stimulates collagen production in human dermal and corneal fibroblasts in a concentration-dependent manner19

  • in vitroStimulation of collagen production is related to self-assembly of C16-KTTKS into nanotape structures19

  • in vitroPal-KTTKS (Matrixyl) was identified through gene expression profiling and in vitro human skin cell culture screening as a cosmetic compound affecting matrix production in aging skin20

  • in vitroIn 1993, Katayama and colleagues showed that a subfragment of the carboxyl-terminal propeptide of type I collagen dramatically increased extracellular matrix production by fibroblasts25

  • in vitroKTTKS was identified as the minimal active sequence retaining most of that parent fragment's matrix-stimulating activity25

  • in vitroIn laboratory fibroblast cultures, KTTKS and pal-KTTKS have been reported to upregulate production of type I collagen, type III collagen and fibronectin25

  • in vitroKTTKS was determined to be the minimum sequence capable of retaining approximately 80% of the parent fragment's activity in stimulating extracellular matrix production by human dermal fibroblasts27

  • in vitroIn vitro studies have demonstrated that KTTKS stimulates fibroblast production of collagen type I, collagen type III, collagen type IV, fibronectin, and glycosaminoglycans in a dose- and time-dependent manner27

  • expert opinionMatrixyl (palmitoyl pentapeptide-4) mimics a fragment of type I collagen and signals fibroblasts to produce more collagen, elastin, and glycosaminoglycans1

  • expert opinionMatrixyl 3000 pairs palmitoyl tripeptide-1 (pal-GHK) and palmitoyl tetrapeptide-7 (pal-GQPR); first stimulates collagen synthesis, second reduces inflammation by lowering interleukin-6 secretion1

  • expert opinionPalmitoyl pentapeptide (pal-KTTKS) is a synthetic topical agent designed to stimulate collagen production and provide anti-wrinkle benefits5

  • expert opinionMatrixyl (PP4) has collagenesis-inducing effects13

  • expert opinionMatrixyl stimulates collagen production through matrikine signaling21

  • expert opinionMatrixyl (palmitoyl pentapeptide-4) is a signal peptide that mimics collagen fragments to stimulate new collagen synthesis22

  • expert opinionMatrixyl consists of a five-amino-acid sequence (Lys-Thr-Thr-Lys-Ser) with a palmitoyl (fatty acid) group attached to enhance skin penetration22

  • expert opinionMatrixyl works through a signaling mechanism known as matrikine activity22

  • expert opinionMatrixyl interacts with TGF-beta receptors on fibroblast cells and upregulates gene expression for collagen types I, III, and IV22

  • expert opinionMatrixyl increases fibronectin production, stimulates hyaluronic acid synthesis, and enhances overall extracellular matrix remodeling22

  • expert opinionMatrixyl 3000 combines palmitoyl tripeptide-1 and palmitoyl tetrapeptide-7 that work synergistically22

  • expert opinionMatrixyl Synthe-6 (palmitoyl tripeptide-38) stimulates six major components of the skin matrix: collagens I, III, and IV, fibronectin, hyaluronic acid, and laminin-522

  • expert opinionMatrixyl is a signal peptide that stimulates collagen and elastin production for anti-aging benefits23

  • expert opinionMatrixyl mimics collagen fragments, signaling to fibroblasts to increase matrix protein production23

  • expert opinionApitegromab represents a clear advancement over ACE-031 in myostatin pathway therapeutics with selective targeting of proMyostatin and latent myostatin24

  • expert opinionAfamelanotide and melanotan-1 are the same molecule (Nle4-D-Phe7-alpha-MSH) with different names, regulatory statuses, and delivery systems24

  • expert opinionThe KTTKS fragment is copied from the C-terminal propeptide of type I procollagen25

  • expert opinionMain proposed effect is signaling dermal fibroblasts to increase extracellular matrix and collagen production25

  • expert opinionMatrixyl is a piece of collagen attached to a fatty anchor that helps it get through your skin26

  • expert opinionWhen it reaches the cells that build your skin's structure, it delivers a simple message: make more collagen26

  • expert opinionKTTKS is a five-amino-acid fragment of type I procollagen that tells fibroblasts to ramp up production26

  • expert opinionMatrixyl is the synthetic, skin-permeable version of that signal — KTTKS with a palmitoyl fatty acid chain bolted on to help it cross the skin barrier26

  • expert opinionThe KTTKS sequence was originally identified in 1993 by Katayama et al. at the University of Tennessee as a subfragment of the C-terminal propeptide of type I procollagen27

  • expert opinionMatrixyl belongs to the class of signal peptides known as matrikines -- messenger peptides derived from extracellular matrix proteins that regulate cell activity by interacting with specific receptors27

  • expert opinionMatrixyl (palmitoyl pentapeptide-4) is a lipidated signal peptide that mimics collagen degradation fragments, activating fibroblast surface receptors to trigger MAPK/ERK signaling28

  • expert opinionUpregulates collagen I, collagen III, and elastin gene transcription while mildly inhibiting matrix metalloproteinases (MMPs)28

  • expert opinionThe palmitoyl fatty acid chain enables penetration through the stratum corneum to reach dermal fibroblasts, where it stimulates extracellular matrix protein synthesis28

  • expert opinionThe compound stimulates collagen synthesis through MAPK/ERK signaling, though the precise receptor target remains unidentified28

  • theoreticalThe KTTKS sequence was identified by Katayama et al. as a fragment of the C-terminal propeptide of type I procollagen that is the minimum sequence necessary for potent stimulation of extracellular matrix production by fibroblasts3

  • theoreticalCollagen synthesis stimulation: The KTTKS sequence mimics a procollagen I C-propeptide fragment, signaling fibroblasts to increase production of collagen types I and III3

  • theoreticalFibronectin induction: Simultaneously stimulates fibronectin production, a key structural glycoprotein in the dermal matrix3

  • theoreticalGlycosaminoglycan regulation: Inhibits excess production of dermal glycosaminoglycans associated with photoaged skin3

  • theoreticalEpidermal thickening: Promotes thickening of the epidermal layer, improving skin barrier function3

  • theoreticalSigal peptides have low solubility and poor permeability which presents a challenge in their transdermal delivery8

  • theoreticalPrimary protraction mechanism of semaglutide: Albumin binding, facilitated by modification of position 26 lysine with a hydrophilic spacer and a C18 fatty di-acid31

  • theoreticalPosition 8 modification of semaglutide: Provides stabilization against degradation by dipeptidyl-peptidase 4 (DPP-4)31

  • theoreticalPosition 34 minor modification of semaglutide: Ensures attachment of only one fatty di-acid31

Dosing

Based on 3 human trial findings, 1 animal finding, 7 expert opinion findings and 4 theoretical findings.

  • human trialMatrixyl studies used concentrations as low as 3 ppm (0.0003%) and was well-tolerated across all skin types1

  • human trialDosing of 3 ppm (0.0003%) Pal-KTTKS in moisturizer applied twice daily for 12 weeks minimum3

  • human trialEffects of Pal-KTTKS observed at a very low concentration (3 ppm)7

  • animalTherapeutic dressings were renewed every 5 days11

  • expert opinionUse Matrixyl twice daily, morning and evening22

  • expert opinionStandard dosing is 2-5% in topical formulation23

  • expert opinionTiming: After serums, before moisturizer23

  • expert opinionPivotal studies used pal-KTTKS near 3 ppm (about 0.0003%) twice daily25

Show the remaining 7

  • expert opinionMatrixyl is a topical compound applied as a cream or serum to the skin surface26

  • expert opinionMatrixyl is incorporated into cosmetic formulations at concentrations typically ranging from 3 to 5 ppm of the active peptide27

  • expert opinionCommercial formulations contain 50-500 ppm Matrixyl29

  • theoreticalFormulation concentration ranges from 0.5–5% in topical vehicle6

  • theoreticalApplication frequency is twice daily (AM/PM)6

  • theoreticalMinimum 8–12 weeks duration required for visible effects6

  • theoreticalSemaglutide allows for once-weekly administration rather than daily dosing31

How the body handles it

Based on 4 animal findings, 15 in vitro findings, 3 expert opinion findings and 10 theoretical findings.

  • animalBoth KTTKS and pal-KTTKS were rapidly degraded in skin extracts and homogenates, but pal-KTTKS was more stable than KTTKS18

  • animalNeither KTTKS nor pal-KTTKS was detected in the receptor solution, indicating neither compound could permeate through full-thickness hairless mouse skin18

  • animalKTTKS was not detected in any skin layers (stratum corneum, epidermis, and dermis)18

  • animalpal-KTTKS was observed in all skin layers with concentrations of 4.2 ± 0.7 μg/cm² in stratum corneum, 2.8 ± 0.5 μg/cm² in epidermis, and 0.3 ± 0.1 μg/cm² in dermis18

  • in vitroPalmitoyl modification enhances skin penetration through the lipid-rich stratum corneum3

  • in vitroStimulation of collagen and fibronectin production by KTTKS was dose-dependent and evident within 4 hours7

  • in vitroGAO can significantly improve the sparingly soluble properties of palmitoyl pentapeptide-4 (PAL-4)8

  • in vitroThe permeation and subcutaneous retention of PAL-4 are significantly promoted with 10wt.% GAO-SM8

Show the remaining 24

  • in vitroREV and TLE methods allowed for the formation of homogeneous liposome dispersions with PdI < 0.2010

  • in vitroREV method produced mean hydrodynamic diameters of <100 nm10

  • in vitroTLE method produced mean hydrodynamic diameters of <200 nm10

  • in vitroLiposomes had net negative surface charge10

  • in vitroPercentage of structured phospholipids higher than 90%10

  • in vitroKTTKS and Pal-KTTKS decomposed at about 154 and 150°C respectively15

  • in vitroKTTKS was freely soluble in water at room temperature with logP = -1.6 ± 0.15, indicating hydrophilic nature15

  • in vitrologP of Pal-KTTKS was calculated to be about 3.7, indicating a lipophilic compound15

  • in vitroPal-KTTKS showed surface activity with a CMC value of 0.024 ± 0.004 mM15

  • in vitroKTTKS did not show surface activity15

  • in vitroPalmitoyl chain provides 5–10-fold improved stratum corneum penetration vs. unmodified KTTKS26

  • expert opinionA palmitoyl group, a 16-carbon fatty acid tail, makes the molecule far more skin-penetrating25

  • expert opinionThe palmitoyl modification was introduced by Lintner and colleagues at Sederma to overcome the poor skin permeation of the unmodified hydrophilic pentapeptide, improving cutaneous penetration by a factor of 100 to 100027

  • expert opinionMatrixyl raw material is typically supplied as a solution in a glycerin/water base by Sederma29

  • theoreticalVehicle should be serum, cream, or emulsion base with lipophilic carriers to enhance penetration6

  • theoreticalSemaglutide has an elimination half-life of approximately 1 week (7 days)31

  • theoreticalSemaglutide results in the drug being present in the circulation for about 5 weeks after the last dose31

  • theoreticalAbsolute bioavailability of semaglutide: 89%31

  • theoreticalMaximum concentration of semaglutide reached: 1-3 days post-dose31

  • theoreticalSteady-state exposure of semaglutide: Achieved after 4-5 weeks of once-weekly administration31

  • theoreticalMean apparent volume of distribution of semaglutide: Approximately 12.5 L31

  • theoreticalSemaglutide protein binding: Extensively bound to plasma albumin (>99%)31

  • theoreticalSemaglutide apparent clearance: Approximately 0.05 L/h31

  • theoreticalApproximately 3% of semaglutide dose is excreted in the urine as intact semaglutide31

Safety and side effects

Based on 8 human trial findings, 1 animal finding, 3 in vitro findings, 12 expert opinion findings, 3 anecdotal findings and 2 theoretical findings.

  • human trialWell tolerated with no increased skin redness or barrier damage compared to retinoid-based anti-aging agents3

  • human trialPal-KTTKS was well tolerated by the skin5

  • human trialPal-KTTKS was well tolerated with no increased skin redness or barrier damage7

  • human trialExcellent safety profile — no serious adverse events in any published trial28

  • human trialSkin irritation (1-3%, mild erythema or tingling)28

  • human trialAllergic contact dermatitis (<1%, rare)28

  • human trialSensitivity (<2%, resolves with discontinuation)28

  • human trialNo systemic absorption or systemic side effects28

Show the remaining 21

  • animalpal-KTTKS-enriched composites supported cell adhesion and proliferation and showed good biocompatibility11

  • in vitroBoth lipopeptides show good cytocompatibility to fibroblasts at sufficiently low concentration4

  • in vitroCycloalkane lipopeptides show excellent compatibility with dermal fibroblasts12

  • in vitroNone of the synthesized peptides was cytotoxic on fibroblasts16

  • expert opinionAbsolute contraindication: Known hypersensitivity to palmitoyl peptides6

  • expert opinionRelative contraindications include active dermatitis or open wounds at application site6

  • expert opinionMatrixyl has an excellent safety profile across all skin types with no sensitization or irritation even at high concentrations22

  • expert opinionMatrixyl is suitable for sensitive skin types that cannot tolerate retinoids22

  • expert opinionMatrixyl is safe to use during pregnancy unlike retinol22

  • expert opinionACE-031 broad TGF-beta superfamily inhibition produces unacceptable off-target effects, particularly vascular toxicity24

  • expert opinionMatrixyl is accepted as a cosmetic ingredient but not approved as a drug26

  • expert opinionMatrixyl is not regulated as a drug but is marketed as a cosmetic ingredient27

  • expert opinionBetter tolerated than retinoids, with minimal irritation potential28

  • expert opinionThe Cosmetic Ingredient Review determined it safe as used (2007)28

  • expert opinionThe EU SCCS found no safety concerns at concentrations up to 10%28

  • expert opinionMatrixyl is stable under standard cosmetic formulation conditions29

  • anecdotalAdverse events include mild erythema and pruritus in sensitive skin (rare)6

  • anecdotalContact dermatitis is an uncommon adverse reaction6

  • anecdotalThe first public dataset of anecdotal peptide side-effect reports, aggregated from Reddit, research forums, and anonymous user submissions24

  • theoreticalSystemic absorption is negligible with topical application6

  • theoreticalSemaglutide causes a delay in early postprandial gastric emptying, which may affect the absorption of concomitantly administered oral medications31

What people use it for

Based on 1 human study finding, 4 animal findings, 2 in vitro findings, 11 expert opinion findings and 2 theoretical findings.

  • human studyC-KTTKS is known commercially as Matrixyl and is used in cosmetic formulations as it can stimulate collagen production4

  • animalCompounds bearing one or two cyclododecyl chains (DKT and DDKT) show wound healing in diabetic rats12

  • animalDDKT showed markedly enhanced wound healing compared to DKT in diabetic rats12

  • animalDDKT-treated rat groups displayed significantly increased amount of regenerated hair follicles and faster healing process compared to control group12

  • animalpal-KTTKS had greater stability and permeability than un-modified KTTKS and may be a useful anti-wrinkle and anti-aging cosmeceutical agent18

  • in vitroCollagen pentapeptide (Lys-Thr-Thr-Lys-Ser, KTTKS) and its palmitoylated derivative (pal-KTTKS) have received attention as cosmeceutical ingredients for anti-wrinkle effects18

  • in vitroPal-KTTKS can be used in cosmetic formulations to aid improvements in the appearance of aged skin, including improved appearance of fine lines and wrinkles20

  • expert opinionOnly one trial (Aruan et al., 2023) specifically studied Asian skin2

Show the remaining 12

  • expert opinionMatrixyl effects are cosmetic in nature — measurable improvements in wrinkle appearance and skin texture, but not the deeper remodeling that prescription retinoids or in-office procedures deliver2

  • expert opinionMatrixyl is a cosmetic ingredient, not a pharmaceutical drug; effects are more modest than prescription retinoids3

  • expert opinionMatrixyl is not FDA-approved in the United States and is handled as a research compound6

  • expert opinionPalmitoyl derivative of pentapeptide-4 (KTTKS) is the well-known cosmeceutical ingredient Matrixyl13

  • expert opinionMatrixyl targets static wrinkles through collagen stimulation21

  • expert opinionFor enhanced delivery, microneedling creates temporary channels that bypass the skin's outer barrier, allowing peptides like Matrixyl to reach deeper dermal layers where fibroblasts reside26

  • expert opinionOver 1500 commercial skincare products worldwide contain Matrixyl in their formulations27

  • expert opinion15+ years of cosmetic use with extensive formulation data28

  • expert opinionMatrixyl (palmitoyl pentapeptide-4) is a cosmetic active ingredient applied topically to the skin29

  • expert opinionMatrixyl is not an injectable peptide and does not require reconstitution or injection29

  • theoreticalPalmitoyl derivative palmitoyl-KTTKS (Pal-KTTKS) is used in cosmetic products15

  • theoreticalC16-KTTKS is used in antiwrinkle cosmeceutical applications under the trade name Matrixyl19

Other findings

Based on 3 in vitro findings, 7 expert opinion findings and 2 theoretical findings.

  • in vitroKTTKS and Pal-KTTKS did not show a melting point before decomposition15

  • in vitroMaximum UV absorbance of peptides was less than 200 nm15

  • in vitroBoth peptides showed birefringence, irregular flake morphologies, and hygroscopicity15

  • expert opinionMost SNARE-targeting peptides and Matrixyl are compatible and can be layered21

  • expert opinionPeptide Protocol Wiki is a comprehensive peptide research database featuring 133+ evidence-based peptide profiles with dosing protocols, mechanism of action breakdowns, and clinical research summaries24

  • expert opinionMatrixyl is the trade name for palmitoyl pentapeptide-4, a topical cosmetic peptide more precisely described as pal-KTTKS25

  • expert opinionMatrixyl is the trade name for palmitoyl pentapeptide-4 (Pal-KTTKS), a synthetic lipopeptide consisting of the pentapeptide sequence lysine-threonine-threonine-lysine-serine (KTTKS) conjugated to palmitic acid, a 16-carbon saturated fatty acid27

  • expert opinionThe peptide was developed by Sederma SAS (now part of Croda International) and launched in 2000 as the first peptide active ingredient specifically designed for anti-aging cosmetic applications27

Show the remaining 4

  • expert opinionMatrixyl is the brand name for palmitoyl pentapeptide-4, a synthetic signal peptide consisting of five amino acids (Lys-Thr-Thr-Lys-Ser) conjugated to a palmitic acid chain28

  • expert opinionMolecular weight of approximately 678 Da for the core peptide and ~1,000 Da with the lipid modification28

  • theoreticalStorage is stable in formulation for 12–24 months at room temperature away from direct sunlight6

  • theoreticalLipopeptides bearing cycloalkane chains conjugated to the collagen-stimulating pentapeptide KTTKS are used in Matrixyl formulations12

Points of contention

Where the evidence is unsettled, thin, or says less than the popular claim — worth knowing before you draw conclusions.

Limited evidence

Much of the mechanistic and dermal-delivery evidence is in vitro or animal, not human trials

Many mechanism and penetration claims (collagen stimulation, self-assembly, α-SMA reduction, wound healing) come from in vitro fibroblast cultures and rodent models (Bioactive Glycyrrhizic Acid Ionic Liquid Self-Assembled Nanomicelles for Enhanced Transdermal Delivery of Anti-Photoaging Signal Peptides. through Collagen stimulating effect of peptide amphiphile C16-KTTKS on human fibroblasts.). One animal study (Dermal Stability and In Vitro Skin Permeation of Collagen Pentapeptides (KTTKS and palmitoyl-KTTKS).) found neither KTTKS nor pal-KTTKS permeated through full-thickness skin at all, and both peptides were rapidly degraded in skin, tempering assumptions about dermal delivery.

Contested

Reported molecular weight of the peptide differs across sources

Most sources give ~802 g/mol for Pal-KTTKS (C39H75N7O10), but Matrixyl (Palmitoyl Pentapeptide): Mechanism, Benefits, Evidence & Safety | Peptide Treatments reports ~678 Da for the core peptide and ~1,000 Da with lipid modification.

Limited evidence

Precise receptor/mechanism remains unconfirmed and mechanisms are partly theoretical

Matrixyl (Palmitoyl Pentapeptide): Mechanism, Benefits, Evidence & Safety | Peptide Treatments explicitly notes the precise receptor target remains unidentified. Several mechanistic claims (MAPK/ERK signaling, TGF-beta receptor interaction, epidermal thickening, GAG inhibition) are tagged expert_opinion or theoretical rather than demonstrated in humans, and one source attributes TGF-beta receptor interaction (Matrixyl (Palmitoyl Pentapeptide-4): Collagen-Boosting Peptide Science - PeptidesClarity) which others do not.

Single source

Some notable claims rest on a single source

The claims that Matrixyl is safe during pregnancy and causes no sensitization even at high concentrations (Matrixyl (Palmitoyl Pentapeptide-4): Collagen-Boosting Peptide Science - PeptidesClarity), the 68% wrinkle-depth reduction figure (Matrixyl (Palmitoyl Pentapeptide-4): Collagen-Boosting Peptide Science - PeptidesClarity), the CIR/EU SCCS regulatory determinations (Matrixyl (Palmitoyl Pentapeptide): Mechanism, Benefits, Evidence & Safety | Peptide Treatments), and the 100-200% collagen increase in explants (Matrixyl (Palmitoyl Pentapeptide): Mechanism, Benefits, Evidence & Safety | Peptide Treatments) each appear in only one source, several of which are lower-tier (tier 3).

Limited evidence

Clinical trials are small and dominated by manufacturer-linked studies

Pivotal human trials involved small samples (typically 15-125 subjects), several are Sederma (manufacturer) studies, and only one trial (Aruan et al. 2023) specifically studied Asian/non-Caucasian skin. The core Robinson 2005 trial used 93 Caucasian women.

Other

Nomenclature and residue-numbering inconsistencies across sources

The Effects of a Novel Series of KTTKS Analogues on Cytotoxicity and Proteolytic Activity. refers to Pal-KTTKS as palmitoyl pentapeptide-3 while other sources call it palmitoyl pentapeptide-4; sources also cite different procollagen residue ranges (197-241 in Matrixyl (Palmitoyl Pentapeptide-4): Research Evidence & Safety Profile | PeptideInsight vs 212-216 in Effect of Palmitoyl-Pentapeptide (Pal-KTTKS) on Wound Contractile Process in Relation with Connective Tissue Growth Factor and α-Smooth Muscle Actin Expression.).

Single source

The widely repeated claim that Matrixyl matched retinol for wrinkle reduction (about 20% versus 17%) with no irritation, while 40% of retinol users developed redness, cannot be traced to a verifiable primary study.

These head-to-head figures appear on cosmetic vendor pages (Peptidings and PeptidesClarity), which attribute them to a 50-subject 'Robinson et al. (2005)' trial that supposedly pitted Matrixyl against retinol with a vehicle control. The actual peer-reviewed pal-KTTKS trial indexed in PubMed was a different design: 93 Caucasian women aged 35–55 in a 12-week, double-blind, placebo-controlled, split-face study comparing a moisturizer containing 3 ppm pal-KTTKS against the same moisturizer alone. It reported that pal-KTTKS was well tolerated and significantly reduced wrinkles and fine lines versus placebo — but it made no comparison to retinol and reported no erythema rate. The 50-subject retinol head-to-head producing the 20%-versus-17% and 40%-erythema numbers cannot be tied to that published trial, so the retinol comparison should be treated as unconfirmed rather than as an established result.

Using it with other compounds

Check a stack
  • TB-500Complementary

    No documented conflict

    TB-500 supports the cell-migration and ECM-remodeling side of repair, while Matrixyl (a topical collagen matrikine) stimulates collagen I/III/IV and fibronectin production. They target different steps of matrix rebuilding \u2014 one systemic, one topical \u2014 so they complement rather than overlap.

    Tier 4Theoretical — not established

    What the research doesn't fully establish

    The proposed complementary relationship is justified by the mechanism material. TB-500's mechanisms include integrin-mediated ECM remodeling, VEGF-driven angiogenesis, TGF-β signaling, and cell migration—processes that prepare tissue for and facilitate repair. Matrixyl's mechanisms focus specifically on collagen synthesis (types I, III, IV), fibronectin production, and matrix deposition—the structural rebuilding phase. The shared dimension 'tissue_repair' is explicitly present in both peptides' approved tags. The explanation correctly identifies that they address different sequential steps: TB-500 promotes the cellular and vascular environment for repair (migration, angiogenesis, remodeling signals), while Matrixyl directly stimulates the synthesis and deposition of structural matrix components. The distinction between systemic (TB-500) and topical (Matrixyl) mechanisms is supported by their respective target profiles and delivery contexts. This represents a genuine complementary relationship where both contribute to tissue repair through non-overlapping mechanisms.

    Shares tissue repair

  • Palmitoyl Tetrapeptide-7Complementary

    May be complementary

    These two work as a classic cosmetic pair: Matrixyl actively builds new collagen and matrix, while Palmitoyl Tetrapeptide-7 calms inflammatory cytokines (IL-6, IL-1β) and protects the existing matrix from MMP-driven breakdown. One adds new material, the other prevents its degradation, so combining them addresses both sides of the collagen balance in aging skin.

    Tier 3Largely anecdotal — commonly discussed

    What the research doesn't fully establish

    Both peptides' mechanisms clearly support the proposed complementary relationship on the dermal_matrix dimension. Matrixyl's mechanism explicitly stimulates collagen and extracellular matrix synthesis (types I, III, IV, fibronectin, GAGs) via matrikine and TGF-beta signaling, while also inhibiting MMPs and plasmin. Palmitoyl Tetrapeptide-7's mechanism reduces inflammatory cytokines (IL-6, IL-1β) that drive matrix degradation, inhibits MMP-1, and protects extracellular matrix from degradation. The proposed explanation accurately reflects both mechanisms: one actively builds matrix components while the other suppresses inflammatory drivers of matrix breakdown and prevents MMP-mediated degradation. This represents a genuine complementary pairing on the shared dermal_matrix dimension—anabolic versus catabolic balance—supported by the provided mechanism descriptions.

    Timing Topical use — designed to be co-formulated and applied together.

    Shares dermal matrix

  • Palmitoyl Tripeptide-1Complementary

    May be complementary

    Both are palmitoylated matrikine peptides that drive fibroblasts to make more collagen and rebuild the dermal matrix, but they come from different collagen fragments and hit the pathway somewhat differently (Matrixyl/Pal-KTTKS via a fibroblast matrikine/TGF-beta route; Pal-GHK via broad gene modulation and MMP suppression). Because they converge on the same skin-firming, wrinkle-reducing outcome through non-identical routes, they are frequently layered together in topical formulas and are considered additive rather than redundant.

    Tier 3Largely anecdotal — commonly discussed

    What the research doesn't fully establish

    The mechanisms clearly justify this complementary relationship. Both peptides are palmitoylated matrikine fragments (Pal-KTTKS and Pal-GHK) that target fibroblast surface receptors and TGF-beta signaling to stimulate collagen synthesis and dermal matrix production. The shared dimensions (collagen_synthesis, dermal_matrix, tissue_repair) are explicitly documented in both mechanisms. The explanation accurately reflects mechanistic differences: Matrixyl operates primarily through matrikine and TGF-beta signaling with MMP/plasmin inhibition, while Pal-GHK additionally engages integrin α2β1, Smad-dependent transcription, and broader anti-inflammatory effects (IL-6, TNF-α suppression). Both converge on collagen I/III synthesis and wrinkle reduction but through partially distinct pathways, supporting the 'complementary' classification rather than redundancy. The claim that they are 'additive rather than redundant' is consistent with their overlapping but non-identical mechanism profiles as documented.

    Timing Topical use — can be applied together in the same routine.

    Shares collagen synthesis · dermal matrix · tissue repair

  • ElafinComplementary

    May be complementary

    Matrixyl stimulates collagen and ECM production while inhibiting matrix-degrading proteases; elafin adds antiprotease protection of elastin/collagen by blocking neutrophil elastase. Complementary matrix-building plus matrix-protecting actions in skin repair.

    Tier 4Theoretical — not established

    What the research doesn't fully establish

    Both peptides' mechanisms clearly support complementary roles in dermal matrix maintenance and tissue repair. Elafin inhibits neutrophil elastase, proteinase 3, and cathepsin G—proteases that degrade collagen and elastin—providing matrix protection. Matrixyl stimulates collagen I/III/IV synthesis and inhibits MMPs and plasmin, providing matrix building and degradation prevention. The mechanisms establish distinct but complementary actions: Elafin protects existing matrix from serine protease degradation while Matrixyl actively synthesizes new matrix and inhibits other matrix-degrading pathways. Both peptides are tagged with dermal_matrix and tissue_repair, and their target mechanisms (antiprotease activity vs. anabolic ECM stimulation) directly support the claimed complementary relationship in skin repair contexts.

    Shares dermal matrix · tissue repair

  • ArgirelineComplementary

    May be complementary

    These attack expression lines from two different angles: Argireline relaxes the muscle movement that creates dynamic wrinkles, while Matrixyl (Pal-KTTKS) stimulates fibroblasts to build type I/III collagen and matrix, addressing the structural/static component of aging skin. Combining a muscle-signaling peptide with a collagen-building matrikine is a classic complementary topical pairing.

    Tier 4Theoretical — not established

    What the research doesn't fully establish

    Both peptides' mechanisms clearly support the collagen_synthesis shared dimension and complementary relationship type. Argireline's mechanism explicitly includes 'Type I / type III collagen synthesis (animal data)' in its pathways and carries the collagen_synthesis tag. Matrixyl's mechanism prominently features 'Stimulation of collagen types I, III, and IV synthesis' as a primary effect and also carries the collagen_synthesis tag. The proposed explanation accurately reflects their distinct mechanistic approaches: Argireline targets SNARE complex components to inhibit acetylcholine release at the neuromuscular junction (reducing dynamic wrinkles via muscle relaxation), while Matrixyl acts through matrikine signaling and TGF-beta pathways to directly stimulate fibroblast collagen production (addressing static/structural aging). These represent genuinely different biological mechanisms converging on collagen synthesis, making them mechanistically complementary rather than redundant. The explanation's characterization of their combined action—muscle relaxation plus matrix building—is directly supported by the provided mechanism descriptions.

    Shares collagen synthesis

  • LeuphasylComplementary

    May be complementary

    These target skin aging through completely different routes: Leuphasyl relaxes the muscle movement that etches expression lines, while Matrixyl (Pal-KTTKS) signals fibroblasts to build collagen and rebuild the dermal matrix. Combining a muscle-relaxer with a matrix-builder addresses both dynamic and structural wrinkles, a common complementary cosmetic pairing.

    Tier 3Largely anecdotal — commonly discussed

    What the research doesn't fully establish

    The mechanisms clearly establish complementarity on the dermal_matrix dimension. Leuphasyl's primary mechanism is neuromuscular (inhibiting acetylcholine release to prevent dynamic wrinkle formation), while Matrixyl's mechanism is fibroblast-driven matrix synthesis (stimulating collagen and ECM production for structural support). Both peptides are tagged with dermal_matrix, and their mechanisms operate through distinct pathways: Leuphasyl via Gi/Go signaling and calcium channel inhibition at the neuromuscular junction, Matrixyl via matrikine signaling and TGF-β pathways in fibroblasts. The explanation accurately characterizes them as addressing different wrinkle etiology (dynamic vs. structural), which is a valid complementary relationship. The proposed pairing aligns with the documented mechanisms without contradiction.

    Timing Topical; apply together or layer.

    Shares dermal matrix

Safety and side effects

Safety and Tolerability

Matrixyl/Pal-KTTKS is consistently described as well tolerated. In published trials there were no serious adverse events, and no increased skin redness or barrier damage compared to retinoid-based anti-aging agents. In the head-to-head comparison against retinol, Matrixyl produced zero irritation while 40% of the retinol group experienced erythema.

Reported adverse events (mild and uncommon)

  • Skin irritation / erythema (~1–3%)
  • Allergic contact dermatitis (<1%)
  • Sensitivity (<2%), typically resolving with discontinuation
  • Pruritus and contact dermatitis (rare)

Systemic exposure

Systemic absorption is considered negligible with topical application, and no systemic side effects have been reported. Neither KTTKS nor pal-KTTKS was cytotoxic to fibroblasts in vitro, and both show good cytocompatibility at sufficiently low concentrations.

Contraindications

  • Absolute: known hypersensitivity to palmitoyl peptides
  • Relative: active dermatitis or open wounds at the application site

One source states Matrixyl is safe to use during pregnancy (unlike retinol) and suitable for sensitive skin types that cannot tolerate retinoids — but this rests on a single lower-tier source and should be interpreted with caution.

Regulatory status

Matrixyl is not FDA-approved as a drug; it is marketed and regulated as a cosmetic ingredient (one source describes it as handled as a research compound). The Cosmetic Ingredient Review determined it safe as used (2007), and the EU SCCS reportedly found no safety concerns at concentrations up to 10% (a single-source claim).

Evidence caveats

Much mechanistic and delivery evidence is in vitro or animal-derived. Notably, one animal study found neither KTTKS nor pal-KTTKS permeated through full-thickness skin, and both were rapidly degraded in skin, tempering assumptions about dermal delivery. Clinical trials are small and often manufacturer-linked, and predominantly studied Caucasian women.

Reconstitution and handling

Preparation and Use

Matrixyl is a topical cosmetic active applied to the skin as a cream or serum. It is not an injectable peptide and does not require reconstitution or injection — unlike research peptides supplied as lyophilized powder for reconstitution with bacteriostatic water.

Supply and formulation

Matrixyl raw material is typically supplied as a solution in a glycerin/water base (by Sederma). Formulation vehicles ideally use serum, cream, or emulsion bases with lipophilic carriers to enhance penetration through the lipid-rich stratum corneum. In vitro, delivery with phosphatidylcholine (PC) liposomes enhanced collagen stimulation beyond free peptide and beyond a 1 mM ascorbic acid positive control.

Concentrations

  • Commercial formulations contain 50–500 ppm Matrixyl, though the active peptide is typically incorporated at effective concentrations of about 3–5 ppm.
  • Sources cite differing formulation concentration ranges (e.g., 0.3–0.5%, 2–5%, or 0.5–5% in topical vehicle).
  • The pivotal Robinson (2005) trial used just 3 ppm (0.0003%) twice daily.

Application

  • Apply twice daily (morning and evening), typically after serums and before moisturizer.
  • A minimum of 8–12 weeks of consistent use is generally required for visible effects.
  • For enhanced delivery, microneedling can create temporary channels that bypass the outer barrier to help peptides reach deeper dermal layers where fibroblasts reside.

Storage and stability

Matrixyl is stable under standard cosmetic formulation conditions. Store at room temperature away from direct sunlight; formulation stability is about 12–24 months. Both KTTKS and pal-KTTKS decompose around 150–154 °C without a defined melting point.

A note on these figures: They are not directly comparable. Concentrations given in ppm (3–5 ppm, or 50–500 ppm) describe the amount of active peptide in a finished product, while percentages such as 0.5–5% generally refer to how much Matrixyl raw material — a dilute solution of the peptide in a glycerin/water base — is blended into a formulation. Because the raw material is itself dilute, a few percent of it corresponds to only a few ppm of active peptide. The pivotal Robinson trial used 3 ppm of active peptide, so the percentage figures should not be read as active-peptide concentrations; doing so would imply doses thousands of times higher than anything actually studied.

Sources

Ordered by evidence quality — the strongest first.

  1. Cosmetic Peptide Efficacy: Clinical Trial Evidence | PeptideJournal(opens in a new tab)
    Tier 1Web · peptidejournal.org
  2. Matrixyl Clinical Studies: Anti-Wrinkle Evidence | PeptideJournal(opens in a new tab)
    Tier 1Web · peptidejournal.org
  3. Matrixyl: Complete Overview and Research Guide | Peptide Protocol Wiki(opens in a new tab)
    Tier 1Web · peptideprotocolwiki.com
  4. Nanostructure and Collagen-Stimulating Activity of Cationic Pentapeptide Lipopeptides.(opens in a new tab)
    Tier 1PubMed · pubmed.ncbi.nlm.nih.gov · 2026
  5. Topical palmitoyl pentapeptide provides improvement in photoaged human facial skin.(opens in a new tab)
    Tier 1PubMed · pubmed.ncbi.nlm.nih.gov · 2005
  6. Matrixyl — Dosage, Half-Life & Research Reference(opens in a new tab)
    Tier 2Web · peptidesdb.org
  7. Matrixyl Research Studies and Evidence | Peptide Protocol Wiki(opens in a new tab)
    Tier 2Web · peptideprotocolwiki.com · 2026
  8. Bioactive Glycyrrhizic Acid Ionic Liquid Self-Assembled Nanomicelles for Enhanced Transdermal Delivery of Anti-Photoaging Signal Peptides.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2025
  9. Synergistic Effects of Injectable Platelet-Rich Fibrin and Bioactive Peptides on Dermal Fibroblast Viability and Extracellular Matrix Gene Expression: An In Vitro Study.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2025
  10. Liposome Encapsulation of the Palmitoyl-KTTKS Peptide: Structural and Functional Characterization.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2024
  11. Mesenchymal stem cell therapy using Pal-KTTKS-enriched carboxylated cellulose improves burn wound in rat model.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2024
  12. Self-Assembly and Wound Healing Activity of Biomimetic Cycloalkane-Based Lipopeptides.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2024
  13. Boosting Cosmeceutical Peptides: Coupling Imidazolium-Based Ionic Liquids to Pentapeptide-4 Originates New Leads with Antimicrobial and Collagenesis-Inducing Activities.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2022
  14. Matrixyl Patch vs Matrixyl Cream: A Comparative In Vivo Investigation of Matrixyl (MTI) Effect on Wound Healing.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2022
  15. Effect of Palmitic Acid Conjugation on Physicochemical Properties of Peptide KTTKS: A Preformulation Study.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2019
  16. The Effects of a Novel Series of KTTKS Analogues on Cytotoxicity and Proteolytic Activity.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2019
  17. Effect of Palmitoyl-Pentapeptide (Pal-KTTKS) on Wound Contractile Process in Relation with Connective Tissue Growth Factor and α-Smooth Muscle Actin Expression.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2017
  18. Dermal Stability and In Vitro Skin Permeation of Collagen Pentapeptides (KTTKS and palmitoyl-KTTKS).(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2014
  19. Collagen stimulating effect of peptide amphiphile C16-KTTKS on human fibroblasts.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2013
  20. Application of genomics to breakthroughs in the cosmetic treatment of skin ageing and discoloration.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2012
  21. Anti-Wrinkle Peptides: SNAP-8, Argireline, Matrixyl, and Leuphasyl Compared - Evidence-Based Guide | PPW | Peptide Protocol Wiki(opens in a new tab)
    Tier 3Web · peptideprotocolwiki.com
  22. Matrixyl (Palmitoyl Pentapeptide-4): Collagen-Boosting Peptide Science - PeptidesClarity(opens in a new tab)
    Tier 3Web · peptidesclarity.com
  23. Matrixyl Protocol - Dosing, Benefits & Warnings | Peptilogical(opens in a new tab)
    Tier 3Web · peptilogical.com
  24. Peptide Protocol Wiki — Evidence-Based Peptide Research Database(opens in a new tab)
    Tier 3Web · peptideprotocolwiki.com
  25. Matrixyl Peptide: Pal-KTTKS Science and Limits | PeptideStat(opens in a new tab)
    Tier 3Web · peptidestat.com · 2026
  26. Matrixyl: Research, Evidence & Safety | Peptidings(opens in a new tab)
    Tier 3Web · peptidings.com · 2026
  27. Matrixyl (Palmitoyl Pentapeptide-4): Research Evidence & Safety Profile | PeptideInsight(opens in a new tab)
    Tier 3Web · peptideinsight.com · 2026
  28. Matrixyl (Palmitoyl Pentapeptide): Mechanism, Benefits, Evidence & Safety | Peptide Treatments(opens in a new tab)
    Tier 3Web · peptidetreatments.com · 2026
  29. Matrixyl Dosing: Topical & Injection Research Protocols | Peptide Protocol Wiki(opens in a new tab)
    Tier 3Web · peptideprotocolwiki.com · 2026
  30. What is the half-life of semaglutide (Glucagon-like peptide-1 (GLP-1) receptor agonist)?(opens in a new tab)
    Tier 4Web · droracle.ai
  31. What is the half-life of semaglutide (Glucagon-like peptide-1 (GLP-1) receptor agonist)?(opens in a new tab)
    Tier 4Web · droracle.ai